Sponsored by Princeton CME

Target Audience

This activity is designed for clinical and managed care pharmacists.

Learning Objectives

After completing this activity, participants should be able to:

• Describe the burden of acute coronary syndrome (ACS) and the impact of percutaneous coronary intervention (PCI) on clinical and economic outcomes
• Summarize the current standards of care for patients with ACS, including preventive approaches for secondary cardiovascular events
• Outline the benefits and limitations of the use of current and emerging antiplatelet agents before, during, and after PCI
• Implement current evidence-based guidelines and standards to maximize outcomes in ACS management before, during, and after PCI

Credit Eligibility

To be eligible for documentation of credit, participants must participate in the full educational activity, complete the 10-question post-test with a score of 70% or better, and complete the evaluation form. Participants who successfully complete the post-test and evaluation form online may immediately print their documentation of credit.

Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring material.

Release Date: February 29, 2008
Expiration Date: April 11, 2009

Estimated time to complete: 1 hour

There is no fee associated with this activity.

Lecture Components

The presentation slides, post-test, and evaluation form are available as a click through via the menu at the top of each page of this educational activity.

CPE Accreditation
Princeton CME is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education (ACPE Provider #452) and complies with the Criteria for Quality and Interpretive Guidelines. This activity is approved for 1 contact hour (0.1 CEU) of continuing pharmacy education (UPN 452-000-08-002-H01-P).

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity sponsored or cosponsored by Princeton CME may contact the Assistant Director of Continuing Education in writing. The Assistant Director of Education will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Director of Continuing Education may be made for a second level of review.

Grant Support

Supported by an educational grant from Daiichi Sankyo, Inc., and Eli Lilly and Company.

Presenters/Q&A Panel

Daniel M. Kolansky, MD
Director, Cardiac Care Unit and
Associate Professor of Medicine
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania

Paul P. Dobesh, PharmD, FCCP, BCPS
Associate Professor of Pharmacy Practice
College of Pharmacy
University of Nebraska Medical Center
Omaha, Nebraska

Jeffrey D. Dunn, PharmD, MBA
Formulary and Contract Manager
SelectHealth, Inc
Salt Lake City, Utah

Independent Clinical Reviewer

Lewis C. Lipson, MD
Associate Professor of Medicine
Division of Cardiovascular Diseases
University of Virginia Health System
Charlottesville, Virginia

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of Princeton CME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of Princeton CME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are viewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty has reported the following:

Dr. Kolansky: Research Funding, Principal Investigator—Conor Medsystems, Inc; Speaker—Advanced Health Media, Bristol Myers-Squibb/sanofi aventis US. 

Dr. Dobesh: Consultant—sanofi aventis US; Scientific Consultant—Eli Lilly and Company, The Medicines Company. Speaker—sanofi aventis US. 

Dr. Dunn: Scientific Consultant—Eli Lilly and Company.

Dr. Lipson: Speaker—sanofi aventis US.

Planning committee Randy Robbin, John Savage, and Mike Kearney, Princeton CME; Rosemary Hodgson and William Kormos, Princeton Media Communications have disclosed that they have no significant financial relationships.

Princeton CME requires faculty to inform participants whenever off-label/unapproved uses of drugs or devices are discussed in their presentations.

The following off-label/unapproved uses of drugs or devices are discussed: the use of prasugrel and cangrelor for use in ACS or PCI; and higher loading dose levels of clopidogrel than currently approved by the FDA for use in ACS or PCI.